Which sclerosing agent works best for vascular malformations? new study aims to find out
NCT ID NCT07320430
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study compared the effectiveness and safety of different sclerosing agents, including ethanol, for treating low-flow vascular malformations. Seventy-five participants with trunk or extremity lesions received injections under ultrasound guidance. The goal was to see which agent achieved the highest cure rate (complete or partial devascularization) with the fewest side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faculty of medicine Ain Shams University
Cairo, Abbassia, 00202, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ethanol and other sclerosing agents
What this could lead to
If successful, this could identify the safest and most effective sclerosing agent for treating low-flow vascular malformations, improving outcomes and reducing complications.
What could go wrong
This is a completed small study (75 people) comparing existing treatments, so results may not apply to all patients. Risks include pain, skin issues, and allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.